Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of Subcutaneous Tocilizumab in RA
NCT01662063Phase 3Completed
- Sponsor
- Genentech
- Start
- Aug 2012
- Primary completion
- Apr 2014
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 2
01
Overview
Phase 3, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Genentech. Primary endpoints: Serious Adverse Events at 96 weeks and Anti-Tocilizumab Antibodies at 96 weeks. Started Aug 2012; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01662063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662063.